New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.
The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.
